title: Metabolic Correction as a tool to improve diabetes type 2 management.
abstract: Diabetes Mellitus type 2 (DM2) is a metabolic disease that develops by a decrease in sensitivity of insulin receptors as an effect of the disruption certain metabolic functions in the processing of glucose. DM2 patients have, uncontrolled glucose levels, and commonly have problems with obesity and cardiovascular disease. Patients are treated with standard diet, insulin, diabetic oral agents and antihypertensive drugs, but this approach does not completely stops tissue deterioration since it does not address the metabolic root of the disease. Metabolic correction is proposed as a suitable adjunct treatment to improve clinical outcomes. Metabolic correction is based on diet modification, proper hydration and scientific supplementation directed to improve cellular biochemistry and metabolic efficiency. In addition, other possible benefits may include reduction in medication use, disease complications and medical costs. To test the results of a metabolic correction program, 25 patients with DM2 participated in an education program about adequate food consumption that promoted control of blood glucose levels. Anthropometric measurements and blood tests were performed during a 13 week program based on a low carbohydrate diet, proper hydration and magnesium supplementation. The metabolic correction program implemented by a proprietary educational system resulted in significant reductions in glucose, triglycerides, cholesterol, weight and waist circumference. Improvements in these values could represent an important reduction of coronary heart disease risk factors as well as other chronic degenerative diseases. In addition there was medication dosage reduction in one or more medications in 21 of the 25 participating patients, which suggest that the program has the potential to improve health outcomes and reduce health care costs.
authors.forename: Jorge R
authors.initials: JR
authors.lastname: Miranda-Massari
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Gonzalez
authors.forename: Alvarez-Soto
authors.initials: AS
authors.lastname: Fernando
authors.forename: Carlos
authors.initials: C
authors.lastname: Cidre
authors.forename: Iván M
authors.initials: IM
authors.lastname: Paz
authors.forename: Jorge
authors.initials: J
authors.lastname: Charvel
authors.forename: Viridiana
authors.initials: V
authors.lastname: Martínez
authors.forename: Jorge
authors.initials: J
authors.lastname: Duconge
authors.forename: Aileen
authors.initials: A
authors.lastname: Aponte
authors.forename: Carlos M
authors.initials: CM
authors.lastname: Ricart
mesh_terms: D001341:Autonomic Nervous System / Q000503:physiopathology; D001786:Blood Glucose / Q000032:analysis; D003131:Combined Modality Therapy; D015897:Comorbidity; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000378:metabolism / Q000628:therapy*; D050528:Diet, Carbohydrate-Restricted; D003927:Diet, Diabetic; D004327:Drinking Behavior; D050171:Dyslipidemias / Q000150:complications / Q000628:therapy; D006801:Humans; D006946:Hyperinsulinism / Q000150:complications / Q000178:diet therapy; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008055:Lipids / Q000097:blood; D008274:Magnesium / Q000627:therapeutic use; D009765:Obesity / Q000150:complications / Q000178:diet therapy; D010353:Patient Education as Topic / Q000379:methods*; D010865:Pilot Projects; D015397:Program Evaluation; D016896:Treatment Outcome; D055105:Waist Circumference; D015431:Weight Loss
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D008055:Lipids; D008274:Magnesium